Prostatic Neoplasms — Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer
Citation(s)
A Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated With Docetaxel/ Prednisone for Metastatic Androgen-independent Prostate Cancer